Shandong Wohua Pharmaceutical Co Ltd: A Focus on Cardiocerebral Medicine
Shandong Wohua Pharmaceutical Co., Ltd., a prominent player in China’s pharmaceutical sector, has been making significant strides in the development and production of Chinese herbal medicines, particularly those aimed at treating cardiocerebral diseases. Based in Shandong, the company has carved out a niche in the health care industry by focusing on traditional Chinese medicine (TCM) solutions.
As of July 15, 2025, Shandong Wohua’s stock closed at 6.69 CNH on the Shenzhen Stock Exchange, where it has been listed since its IPO on January 24, 2007. The company’s market capitalization stands at 3,760,000,000 CNH, reflecting its substantial presence in the market. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 7.78 CNH on July 14, 2025, and a low of 3.46 CNH on September 17, 2024.
The company’s financial metrics indicate a price-to-earnings ratio of 75.88, suggesting investor confidence in its growth potential despite the high valuation. Shandong Wohua’s commitment to innovation in TCM is evident in its product offerings, which are designed to address complex health issues such as cardiocerebral diseases.
For more detailed information about Shandong Wohua Pharmaceutical Co., Ltd., including its product range and corporate strategies, stakeholders and interested parties can visit their official website at www.wohua.cn . The company continues to focus on expanding its reach and enhancing its product portfolio to meet the growing demand for effective and natural health care solutions.